Evidence map›Paper›PMID 42353275›Full record

ArticleInternational journal of molecular sciences2026

Identification of β-Lapachone as a Potent USP22 Inhibitor That Suppresses Cancer Stemness and Enhances Chemosensitivity in Lung Adenocarcinoma.

Yuanyuan Gao, Keqiang Zhang, Wendong Li, John Liu, David Kwon, Lilian Gu, Aimin Li, Hongwei Holly Yin, Claudia Kowolik, Mahima Raul and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuanyuan GaoDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
Keqiang ZhangDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
Wendong LiDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
John LiuDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
David KwonCancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.
Lilian GuDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
Aimin LiPathology Core of Shared Resources, City of Hope National Medical Center, Duarte, CA 91010, USA.
Hongwei Holly YinCancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.ORCID 0000-0002-5070-663X
Claudia KowolikCancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.
Mahima RaulDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
David A HorneCancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.
Dan J RazDivision of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.

Funding

City Of Hope National Medical Center IDDV-COH33United States Department of Defense W81XWH-22-1-0306
6 · The paper itself

Abstract

Ubiquitin-specific protease 22 (USP22) regulates epigenetic gene expression by deubiquitinating histone H2B (H2Bub1) and upregulating oncogenic proteins and pathways, while antagonizing p53-mediated tumor suppression. USP22 is frequently overexpressed in cancers and associated with therapy resistance and poor prognosis yet remains largely untargeted pharmacologically. Here, using a fluorescence-based USP22 deubiquitinase assay to screen the LOPAC

Indexed as

Adenocarcinoma of LungAntineoplastic AgentsLung NeoplasmsNaphthoquinonesNeoplastic Stem CellsUbiquitin ThiolesteraseAnimalsApoptosisCell Line, TumorCell ProliferationCisplatinDrug Resistance, NeoplasmHumansMiceMolecular Docking SimulationXenograft Model Antitumor AssaysAntineoplastic Agentsbeta-lapachoneCisplatinNaphthoquinonesUbiquitin ThiolesteraseUsp22 protein, humancancer stem cellschemosensitivitydeubiquitinase inhibitorlung adenocarcinoma (LUAD)ubiquitin-specific protease 22 (USP22)β-Lapachone

Identifiers

PMID42353275
PMCPMC13299283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.